Why did the FDA reject Moderna's flu shot?

Regulators pause a high-profile mRNA flu application

U.S. regulators declined to accept Moderna’s application to licence an mRNA-based influenza vaccine, a surprising move that has sparked industry concern. The Food and Drug Administration said the company’s submission did not meet standards for an adequately controlled trial — specifically pointing to the choice of comparator used in Moderna’s study. Agency officials argued that the trial design made it difficult to judge whether the new product met the agency’s requirements for safety and effectiveness.

What happened next and why it matters

Moderna has requested discussions with the FDA to address the deficiencies. Inside the agency, the decision prompted public debate: reviewers expressed willingness to consider the application, but senior leadership ultimately refused to file it for formal review. The refusal halts the regulatory clock and means the vaccine cannot proceed to licensure in the U.S. until the company resolves the FDA’s concerns.

Immediate implications

• Moderna must either provide additional data or redesign aspects of its trial to satisfy the FDA.
• The decision could slow the arrival of mRNA flu options in the U.S., with knock-on effects for manufacturers and vaccination plans.
• The episode has broader industry implications: sponsors will be watching to see how strictly the FDA enforces trial-design expectations for novel vaccine platforms.

Regulators say their priority is ensuring that any new or updated vaccine meets established standards for quality, safety and clear evidence of benefit. Moderna and external vaccine experts have said they remain in dialogue with the agency as the company seeks a path forward.